Can Thermo Fisher Scientific (TMO) Justify Its Valuation After New Lab Product Launches?

Why Thermo Fisher Scientific stock is in focus after new product launches

Thermo Fisher Scientific (TMO) has released several new laboratory instruments in rapid succession, including the Multiskan Ease microplate reader, the EMPAD G2 detector and the Orbitrap Isora mass spectrometers with isotope analysis workflow.

These launches expand Thermo Fisher Scientific’s tools for routine absorbance assays, advanced electron microscopy and molecular-level isotope studies. This gives investors fresh context for assessing the stock’s role in research and diagnostic equipment portfolios.

Set against these launches, Thermo Fisher Scientific’s share price has moved to US$613.78, with short term momentum easing after a strong run. This includes a 30 day share price return of 3.33% and a 90 day share price return of 24.23%, while the 1 year total shareholder return of 26.32% points to solid long term participation in the stock’s gains.

Scan Thermo Fisher Scientific’s latest lab breakthroughs alongside other research equipment leaders by checking the hand picked list of solid balance sheet and fundamentals (53 results) that could complement a science focused portfolio.

After Thermo Fisher Scientific’s strong 90 day share price move, and with the stock only modestly below the average analyst target and an intrinsic estimate, where does a reasonable view of fair value actually land for new buyers today?

Most Popular Narrative: 2.8% Undervalued

Thermo Fisher Scientific’s most followed narrative points to a fair value of $631.42, slightly above the last close at $613.78, which keeps expectations finely balanced.

The analysts have a consensus price target of $631.42 for Thermo Fisher Scientific based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $750.0, and the most bearish reporting a price target of just $520.0.

Read the complete narrative.

Want to understand why this fair value only edges past today’s price rather than racing ahead? The narrative leans on a specific mix of earnings growth, margin expansion and a future P/E that must tighten against sector norms. Curious which combination of these levers needs to hold for that $631.42 figure to stack up.

Result: Fair Value of $631.42 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Thermo Fisher Scientific’s fair value case still hinges on factors like academic and government funding, along with China exposure, which could pressure revenue and margins.

Find out about the key risks to this Thermo Fisher Scientific narrative.

Another View on Thermo Fisher Scientific’s Valuation

While the analyst narrative puts Thermo Fisher Scientific around 2.8% below fair value, the company’s current P/E of 32.6x is slightly above a fair ratio of 32.2x. It also sits below the Global Life Sciences average of 36.6x and a 34.5x peer average. So is this a small valuation cushion or a thin margin for error?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With Thermo Fisher Scientific attracting both concern and optimism, now is a good time to review the numbers yourself and pressure test the story. To see how the current upside potential compares with the key issues on investors’ minds, check the 2 key rewards and 1 important warning sign.

Looking for more Thermo Fisher Scientific style investment ideas?

If Thermo Fisher Scientific has sharpened your interest in quality stocks, do not stop here. Put your capital to work by scanning other focused opportunities that might suit your goals.

• Target steady compounders with strong fundamentals by reviewing companies in the 47 high quality undervalued stocks that may trade below what their cash flows suggest.
• Strengthen your income stream by checking stocks in the 11 dividend fortresses that combine higher yields with an emphasis on resilience.
• Prioritise capital preservation by scanning the 80 resilient stocks with low risk scores that screen for businesses with lower risk scores and sturdier profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com